<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02381288</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-448-2002</org_study_id>
    <secondary_id>U1111-1150-2776</secondary_id>
    <nct_id>NCT02381288</nct_id>
  </id_info>
  <brief_title>Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone</brief_title>
  <official_title>A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects on serum testosterone (ST) after 6 weeks
      of subcutaneous (SC) administration of different doses and dosing frequencies of TAK-448 to
      middle-aged and older men with low ST levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug tested in this study is called TAK-448. TAK-448 was tested to define a dose and dose
      frequency which results in a clinically relevant improvement in ST in middle-aged and older
      men with low ST levels. This study looked at ST levels in men who took TAK-448.

      The study enrolled 17 participants. Participants were randomly assigned (by chance, like
      flipping a coin) to one of the following treatment groups—which remained undisclosed to the
      participants and study doctor during the study (unless there is an urgent medical need):

        -  TAK-448 0.1 µg

        -  TAK-448 0.3 µg

        -  TAK-448 1.0 µg

        -  Placebo (dummy inactive injection) - this was a injection that looks like the study drug
           but has no active ingredient All participants received subcutaneous injection either
           once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on
           Days 1 through 36.

      This single-center trial was conducted in the United States. The overall time to participate
      in this study is up to 56 days. Participants made daily visits to the clinic for 8 weeks, and
      were contacted by telephone 14 days after last dose of study drug for a follow-up assessment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to terminate the study because the study did not meet the primary endpoint.
  </why_stopped>
  <start_date type="Actual">September 10, 2015</start_date>
  <completion_date type="Actual">April 8, 2016</completion_date>
  <primary_completion_date type="Actual">April 8, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change From Baseline in Average Serum Concentration (Cav) of Total ST After 6 Weeks of Dosing</measure>
    <time_frame>Once-daily regimen Day 42; Twice-weekly regimen Day 39; Once-weekly regimen Day 36</time_frame>
    <description>Cav is the average serum concentration of the dosing interval, calculated as area under the effect curve (AUEC) divided by the duration of the dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough Serum Concentration (Ctrough) of ST</measure>
    <time_frame>Once-daily regimen Day 42; Twice-weekly regimen Day 39; Once-weekly regimen Day 36</time_frame>
    <description>Trough serum concentration of total and free ST, defined as lowest Baseline concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Testosterone Cmax: Maximum Observed Plasma Concentration</measure>
    <time_frame>Day 1 (first dose) and Day 42 for once-daily regimen, Day 39 for twice-weekly regimen, or Day 36 for once-weekly regimen (last dose)</time_frame>
    <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Assessments were done Day 1 and Day 42 for once daily regimen, on Day 36 for once weekly regimen and on Day 39 for twice-weekly regimen (Day 42/36/39).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for the Free Form of TAK-448 (TAK-448F)</measure>
    <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
    <description>Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCt: Area Under the Plasma Concentration-Time Curve for TAK-448F</measure>
    <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Elimination Half-life (T1/2) for TAK-448F</measure>
    <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
    <description>T1/2 is the time required for half of the drug to be eliminated from the plasma.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Low Testosterone</condition>
  <arm_group>
    <arm_group_label>TAK-448 0.1 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 0.3 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 0.3 mcg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAK-448 1.0 mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-448 1.0 mcg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-448</intervention_name>
    <description>TAK-448 solution for subcutaneous injection</description>
    <arm_group_label>TAK-448 0.1 mcg</arm_group_label>
    <arm_group_label>TAK-448 0.3 mcg</arm_group_label>
    <arm_group_label>TAK-448 1.0 mcg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-448 Placebo</intervention_name>
    <description>TAK-448 placebo-matching solution for subcutaneous injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has total serum testosterone (ST) levels less than 300 ng/dL at Screening.

          2. Has a body mass index (BMI) between 20.0 and 40.0 kg/m^2, inclusive at Screening.

          3. A male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from the time of signing
             of informed consent throughout the duration of the study and for 12 weeks after the
             last dose.

        Exclusion Criteria:

          1. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other abnormality
             that may impact the ability of the participant to participate or potentially confound
             the study results. Participants will be excluded based on:

               1. Has a serum creatinine &gt;2.0 milligrams per deciliter (mg/dL) at Screening.

               2. Is receiving dialysis treatment.

               3. Has an American Urological Association (AUA)/ International Prostate Symptom
                  Score (I-PSS) score of &gt;19 or serum prostate-specific antigen (PSA) &gt;4 nanogram
                  per milliliter (ng/mL) at Screening.

               4. Has thyrotropin (TSH) levels less than (&lt;) 0.3 or &gt;7.5 milli-international units
                  per liter (mIU/L) at Screening.

               5. Has systolic blood pressure &gt;160 millimeter of mercury (mm Hg) or diastolic blood
                  pressure &gt;100 mm Hg (if out of range may be repeated once for eligibility
                  determination) at Screening.

               6. Has luteinizing hormone (LH) &gt;9.4 units per liter (U/L) at Screening.

               7. Is receiving insulin therapy.

               8. Has a hematocrit &lt;30 percent (%) or &gt;48% at Screening.

               9. Has a glycosylated hemoglobin (HbA1c) &gt;8.0 at Screening (Cohort 1).

          2. Has type 2 diabetes mellitus defined as fasting blood glucose &gt;125 mg/dL, glycosylated
             hemoglobin (HbA1c) &gt;6.2%, or use of antidiabetic medication (Cohort 2 only).

          3. Has clinical evidence of anatomic or pathological hypothalamic/pituitary/testicular
             disease, such as (but not limited to) Klinefelter's syndrome, Kallmann's syndrome,
             systemic infiltrative diseases (hemochromatosis, sarcoidosis, Wilson's disease), or
             prior pituitary surgery.

          4. Has used gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists,
             antiandrogens, clomiphene, or other reproductive hormone-related agents within 6
             months prior to Screening.

          5. Has used anabolic therapies (testosterone, dehydroepiandrosterone [DHEA],
             androstendione, any other androgen, or recombinant human growth hormone) within 1 year
             of Screening.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2015</study_first_submitted>
  <study_first_submitted_qc>March 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2015</study_first_posted>
  <results_first_submitted>April 7, 2017</results_first_submitted>
  <results_first_submitted_qc>April 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2017</results_first_posted>
  <disposition_first_submitted>February 2, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>February 2, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 6, 2017</disposition_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United States from 10 September 2015 to 08 April 2016.</recruitment_details>
      <pre_assignment_details>Middle-aged and older male participants with low testosterone levels were enrolled in once daily TAK-448 0.1 µg, twice weekly TAK-448 0.3 µg, once weekly TAK-448 1 µg or Placebo groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
        </group>
        <group group_id="P2">
          <title>TAK-448 0.1 µg</title>
          <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
        </group>
        <group group_id="P3">
          <title>TAK-448 0.3 µg</title>
          <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
        </group>
        <group group_id="P4">
          <title>TAK-448 1.0 µg</title>
          <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety analysis set included all randomized participants who received at least 1 dose of study drug or placebo.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
        </group>
        <group group_id="B2">
          <title>TAK-448 0.1 µg</title>
          <description>TAK-448 0.1 µg, injection, subcutaneously, once daily on Days 1 through 42.</description>
        </group>
        <group group_id="B3">
          <title>TAK-448 0.3 µg</title>
          <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
        </group>
        <group group_id="B4">
          <title>TAK-448 1.0 µg</title>
          <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.0" spread="3.24"/>
                    <measurement group_id="B2" value="71.0" spread="11.31"/>
                    <measurement group_id="B3" value="70.6" spread="9.32"/>
                    <measurement group_id="B4" value="65.2" spread="1.48"/>
                    <measurement group_id="B5" value="67.1" spread="6.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Non-Hispanic and Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.6" spread="5.81"/>
                    <measurement group_id="B2" value="173.5" spread="3.54"/>
                    <measurement group_id="B3" value="172.4" spread="7.80"/>
                    <measurement group_id="B4" value="174.6" spread="6.77"/>
                    <measurement group_id="B5" value="173.5" spread="6.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.0" spread="16.6"/>
                    <measurement group_id="B2" value="101.6" spread="11.3"/>
                    <measurement group_id="B3" value="99.4" spread="17.3"/>
                    <measurement group_id="B4" value="91.5" spread="21.5"/>
                    <measurement group_id="B5" value="95.5" spread="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" spread="4.3"/>
                    <measurement group_id="B2" value="33.9" spread="5.2"/>
                    <measurement group_id="B3" value="33.3" spread="4.2"/>
                    <measurement group_id="B4" value="30.0" spread="6.5"/>
                    <measurement group_id="B5" value="31.6" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant has never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is an ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Classification</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Participant has never drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is a current drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant is an ex-drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline in Average Serum Concentration (Cav) of Total ST After 6 Weeks of Dosing</title>
        <description>Cav is the average serum concentration of the dosing interval, calculated as area under the effect curve (AUEC) divided by the duration of the dosing interval.</description>
        <time_frame>Once-daily regimen Day 42; Twice-weekly regimen Day 39; Once-weekly regimen Day 36</time_frame>
        <population>Pharmacodynamic (PD) analysis set included all participants who received at least 1 dose of study drug or placebo and who had at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O4">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Average Serum Concentration (Cav) of Total ST After 6 Weeks of Dosing</title>
          <description>Cav is the average serum concentration of the dosing interval, calculated as area under the effect curve (AUEC) divided by the duration of the dosing interval.</description>
          <population>Pharmacodynamic (PD) analysis set included all participants who received at least 1 dose of study drug or placebo and who had at least 1 valid PD measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.32" spread="29.186"/>
                    <measurement group_id="O2" value="7.100" spread="18.102"/>
                    <measurement group_id="O3" value="10.60" spread="12.594"/>
                    <measurement group_id="O4" value="15.80" spread="26.531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Trough Serum Concentration (Ctrough) of ST</title>
        <description>Trough serum concentration of total and free ST, defined as lowest Baseline concentration.</description>
        <time_frame>Once-daily regimen Day 42; Twice-weekly regimen Day 39; Once-weekly regimen Day 36</time_frame>
        <population>PD analysis set included all participants who received at least 1 dose of study drug or placebo and who had at least 1 valid PD measure. Here, number of participants analyzed is the participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O4">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Serum Concentration (Ctrough) of ST</title>
          <description>Trough serum concentration of total and free ST, defined as lowest Baseline concentration.</description>
          <population>PD analysis set included all participants who received at least 1 dose of study drug or placebo and who had at least 1 valid PD measure. Here, number of participants analyzed is the participants who were evaluable for this outcome measure.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.4" spread="94.952"/>
                    <measurement group_id="O2" value="255.5" spread="102.53"/>
                    <measurement group_id="O3" value="135.3" spread="44.515"/>
                    <measurement group_id="O4" value="244.4" spread="61.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Testosterone Cmax: Maximum Observed Plasma Concentration</title>
        <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Assessments were done Day 1 and Day 42 for once daily regimen, on Day 36 for once weekly regimen and on Day 39 for twice-weekly regimen (Day 42/36/39).</description>
        <time_frame>Day 1 (first dose) and Day 42 for once-daily regimen, Day 39 for twice-weekly regimen, or Day 36 for once-weekly regimen (last dose)</time_frame>
        <population>PD analysis set included all participants who received at least 1 dose of study drug or placebo and who have at least 1 valid PD measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O4">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Testosterone Cmax: Maximum Observed Plasma Concentration</title>
          <description>Maximum observed plasma concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. Assessments were done Day 1 and Day 42 for once daily regimen, on Day 36 for once weekly regimen and on Day 39 for twice-weekly regimen (Day 42/36/39).</description>
          <population>PD analysis set included all participants who received at least 1 dose of study drug or placebo and who have at least 1 valid PD measure.</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="287.6" spread="58.518"/>
                    <measurement group_id="O2" value="306.5" spread="68.589"/>
                    <measurement group_id="O3" value="351.2" spread="87.434"/>
                    <measurement group_id="O4" value="427.8" spread="67.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 42/36/39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.8" spread="136.09"/>
                    <measurement group_id="O2" value="287.0" spread="57.983"/>
                    <measurement group_id="O3" value="263.8" spread="82.914"/>
                    <measurement group_id="O4" value="343.0" spread="57.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for the Free Form of TAK-448 (TAK-448F)</title>
        <description>Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
        <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
        <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 µg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for the Free Form of TAK-448 (TAK-448F)</title>
          <description>Cmax is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve.</description>
          <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUCt: Area Under the Plasma Concentration-Time Curve for TAK-448F</title>
        <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration.</description>
        <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
        <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 µg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>AUCt: Area Under the Plasma Concentration-Time Curve for TAK-448F</title>
          <description>Area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentration.</description>
          <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Elimination Half-life (T1/2) for TAK-448F</title>
        <description>T1/2 is the time required for half of the drug to be eliminated from the plasma.</description>
        <time_frame>Once-daily Dosing Days 1 and 42, Twice-weekly Dosing Days 1 and 39, Once-weekly Dosing Days 1 and 36, predose and at multiple time intervals (up to 8 hours) post-dose.</time_frame>
        <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
        <group_list>
          <group group_id="O1">
            <title>TAK-448 0.1 µg</title>
            <description>TAK-448 0.1 µg, injection, subcutaneously, once daily on Days 1 through 42.</description>
          </group>
          <group group_id="O2">
            <title>TAK-448 0.3 µg</title>
            <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
          </group>
          <group group_id="O3">
            <title>TAK-448 1.0 µg</title>
            <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Elimination Half-life (T1/2) for TAK-448F</title>
          <description>T1/2 is the time required for half of the drug to be eliminated from the plasma.</description>
          <population>Due to early termination of the study pharmacokinetic data was not collected and reported.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to Day 56</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>TAK-448 placebo matching injection, subcutaneously, either once daily on Days 1 through 42, or twice weekly on Days 1 through 39 or once weekly on Days 1 through 36.</description>
        </group>
        <group group_id="E2">
          <title>TAK-448 0.1 µg</title>
          <description>TAK-448 0.1 mcg, injection, subcutaneously, once daily on Days 1 through 42.</description>
        </group>
        <group group_id="E3">
          <title>TAK-448 0.3 µg</title>
          <description>TAK-448 0.3 µg, injection, subcutaneously, twice-weekly on Days 1 through 39.</description>
        </group>
        <group group_id="E4">
          <title>TAK-448 1.0 µg</title>
          <description>TAK-448 1.0 µg, injection, subcutaneously, once-weekly on Days 1 through 36.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

